| 1. |
|
|
| 2. |
- Aad, G, et al.
(författare)
-
- 2015
-
swepub:Mat__t
|
|
| 3. |
|
|
| 4. |
- Glasbey, JC, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 5. |
- Bravo, L, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 6. |
- Tabiri, S, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Thomas, HS, et al.
(författare)
-
- 2019
-
swepub:Mat__t
|
|
| 10. |
|
|
| 11. |
- Drake, TM, et al.
(författare)
-
Surgical site infection after gastrointestinal surgery in children: an international, multicentre, prospective cohort study
- 2020
-
Ingår i: BMJ global health. - : BMJ. - 2059-7908. ; 5:12
-
Tidskriftsartikel (refereegranskat)abstract
- Surgical site infection (SSI) is one of the most common healthcare-associated infections (HAIs). However, there is a lack of data available about SSI in children worldwide, especially from low-income and middle-income countries. This study aimed to estimate the incidence of SSI in children and associations between SSI and morbidity across human development settings.MethodsA multicentre, international, prospective, validated cohort study of children aged under 16 years undergoing clean-contaminated, contaminated or dirty gastrointestinal surgery. Any hospital in the world providing paediatric surgery was eligible to contribute data between January and July 2016. The primary outcome was the incidence of SSI by 30 days. Relationships between explanatory variables and SSI were examined using multilevel logistic regression. Countries were stratified into high development, middle development and low development groups using the United Nations Human Development Index (HDI).ResultsOf 1159 children across 181 hospitals in 51 countries, 523 (45·1%) children were from high HDI, 397 (34·2%) from middle HDI and 239 (20·6%) from low HDI countries. The 30-day SSI rate was 6.3% (33/523) in high HDI, 12·8% (51/397) in middle HDI and 24·7% (59/239) in low HDI countries. SSI was associated with higher incidence of 30-day mortality, intervention, organ-space infection and other HAIs, with the highest rates seen in low HDI countries. Median length of stay in patients who had an SSI was longer (7.0 days), compared with 3.0 days in patients who did not have an SSI. Use of laparoscopy was associated with significantly lower SSI rates, even after accounting for HDI.ConclusionThe odds of SSI in children is nearly four times greater in low HDI compared with high HDI countries. Policies to reduce SSI should be prioritised as part of the wider global agenda.
|
|
| 12. |
|
|
| 13. |
- Tarif, M. A. H., et al.
(författare)
-
Design and Control of an Autonomous Electric Catamaran Boat
- 2022
-
Ingår i: 2022 International Conference on Green Energy, Computing and Sustainable Technology, GECOST 2022. - : Institute of Electrical and Electronics Engineers Inc.. - 9781665486637 ; , s. 75-80
-
Konferensbidrag (refereegranskat)
|
|
| 14. |
- De Lara, Shahin, 1966, et al.
(författare)
-
The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014)
- 2019
-
Ingår i: Bmc Cancer. - : Springer Science and Business Media LLC. - 1471-2407. ; 19
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundCurrent prognostic markers cannot adequately predict the clinical outcome of breast cancer patients. Therefore, additional biomarkers need to be included in routine immune panels. FOXA1 was a significant predictor of favorable outcome in primary breast cancer, while Nestin expression is preferentially found in triple-negative tumors with increased rate of nodal metastases, and reduced survival. No studies have investigated the prognostic value of FOXA1 and Nestin expression in breast cancer metastases.MethodsBreast cancer metastases (n=164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression. Cox regression analysis assessed the prognostic value of FOXA1 and Nestin expression.ResultsIn breast cancer metastases, FOXA1 expression was associated with Nestin-negativity, GATA3-positivity, ER-positivity, HER2-positivity and non-triple-negative status (P<0.05). In contrast, Nestin expression was associated with FOXA1-negative, GATA3-negative, ER-negative, and triple-negative metastases (P<0.05). Univariate Cox regression analysis showed FOXA1 expression was predictive of overall survival (OS, P=0.00048) and metastasis-free survival (DMFS, P=0.0011), as well as, distant metastasis-free survival in ER-positive patients (P=0.036) and overall survival in ER-negative patients (P=0.024). Multivariate analysis confirmed the significance of FOXA1 for both survival endpoints in metastatic breast cancer patients (OS, P=0.0033; DMFS, P=0.015).ConclusionsIn our study, FOXA1 was expressed mostly in ER-positive breast cancer metastases. Expression of Nestin was related to triple-negative metastases, where brain was the most frequent metastatic site. These findings highlight the clinical utility of FOXA1 and Nestin expression and warrant their inclusion in routine immunohistochemical panels for breast carcinoma.
|
|
| 15. |
- Fäldt Beding, Anna, et al.
(författare)
-
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
- 2022
-
Ingår i: BMC Cancer. - : Springer Science and Business Media LLC. - 1471-2407. ; 22:1
-
Tidskriftsartikel (refereegranskat)abstract
- The BIRC5 gene encodes for the Survivin protein, which is a member of the inhibitor of apoptosis family. Survivin is found in humans during fetal development, but generally not in adult cells thereafter. Previous studies have shown that Survivin is abundant in most cancer cells, thereby making it a promising target for anti-cancer drugs and a potential prognostic tool.To assess genetic alterations and mutations in the BIRC5 gene as well as BIRC5 co-expression with other genes, genomic and transcriptomic data were downloaded via cBioPortal for approximately 9000 samples from The Cancer Genome Atlas (TCGA) representing 33 different cancer types and 11 pan-cancer organ systems, and validated using the ICGC Data Portal and COSMIC. TCGA BIRC5 RNA sequencing data from 33 different cancer types and matching normal tissue samples for 16 cancer types were downloaded from Broad GDAC Firehose and validated using breast cancer microarray data from our previous work and data sets from the GENT2 web-based tool. Survival data were analyzed with multivariable Cox proportional hazards regression analysis and validated using KM plotter for breast-, ovarian-, lung- and gastric cancer.Although genetic alterations in BIRC5 were not common in cancer, BIRC5 expression was significantly higher in cancer tissue compared to normal tissue in the 16 different cancer types. For 14/33 cancer types, higher BIRC5 expression was linked to worse overall survival (OS, 4/14 after adjusting for both age and tumor grade and 10/14 after adjusting only for age). Interestingly, higher BIRC5 expression was associated with better OS in lung squamous cell carcinoma and ovarian serous cystadenocarcinoma. Higher BIRC5 expression was also linked to shorter progressive-free interval (PFI) for 14/33 cancer types (4/14 after adjusting for both age and tumor grade and 10/14 after adjusting only for age). External validation showed that high BIRC5 expression was significantly associated with worse OS for breast-, lung-, and gastric cancer.Our findings suggest that BIRC5 overexpression is associated with the initiation and progression of several cancer types, and thereby a promising prognostic biomarker.
|
|
| 16. |
- Gomes Guerreiro, Gabriel Miguel, et al.
(författare)
-
Cross-Country faults in resonant-grounded networks : Mathematical modelling, simulations and field recordings
- 2021
-
Ingår i: Electric power systems research. - : Elsevier BV. - 0378-7796 .- 1873-2046. ; 196
-
Tidskriftsartikel (refereegranskat)abstract
- Cross-Country Faults (CCFs) are defined by the occurrence of two Single Phase-to-Ground faults taking place simultaneously in different phases and at different locations of the galvanically connected network. Few studies about these faults in MV systems have been done so far, particularly with real fault data and simulations. In this work, first a mathematical model is derived to understand basic properties of CCFs. Then, simulations in RSCAD/RTDS (R) using real data obtained from an utility in Scandinavia are discussed and validated with two real faults measured in the field for resonant-grounded networks in Sweden and Norway. The mathematical calculations proved to have a good accuracy and showed important properties of CCFs such as the dependency of both faults of each others fault resistance and location. Furthermore, it was observed that such faults can be very different from more common types of faults in the power system. Interesting behaviors can appear particularly when feeders are connected in ring, where an extra current with smaller magnitude and 180 degrees appears on the measurement point, as well as in lines with double infeed where a very large difference is detected depending on the fault location which influences directly both ends of the line.
|
|
| 17. |
- Johnatty, S. E., et al.
(författare)
-
No evidence that GATA3 rs570613 SNP modifies breast cancer risk
- 2009
-
Ingår i: Breast Cancer Research and Treatment. - : Springer. - 0167-6806 .- 1573-7217. ; 117:2, s. 371-379
-
Tidskriftsartikel (refereegranskat)abstract
- GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P trend = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (ORper-allele = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (ORper-allele = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RRper-allele = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RRper-allele = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.
|
|
| 18. |
- Maamar, Zakaria, et al.
(författare)
-
Towards an Approach for Weaving Preferences into Web Services Operation
- 2012
-
Ingår i: Journal of Software. - : Academy Publisher. - 1796-217X. ; 7:7, s. 1429-1439
-
Tidskriftsartikel (refereegranskat)abstract
- Existing approaches on Web services privacy dominate solutions from a users' perspective, giving little consideration to the preferences of Web service providers. The integration of service providers' preferences into Web services' operations is discussed in this paper. A Web service provider indicates peer Web services that it could interact with as well as the data that they could exchange with. We focus on Privacy and (trust) Partnership preferences based on which, we develop a Specification for Privacy and Partnership Preferences (S3P). This specification suggests a list of exceptional actions to deploy at run-time when these preferences are not met. An integration model of these preferences into Web services design is illustrated throughout a running scenario, and an implementation framework proves the S3P concept. Towards an Approach for Weaving Preferences into Web Services Operation (PDF Download Available). Available from: https://www.researchgate.net/publication/235724905_Towards_an_Approach_for_Weaving_Preferences_into_Web_Services_Operation [accessed Mar 22, 2016].
|
|
| 19. |
- Mathew, Sujith Samuel, et al.
(författare)
-
Building sustainable parking lots with the Web of Things
- 2014
-
Ingår i: Personal and Ubiquitous Computing. - : Springer. - 1617-4909 .- 1617-4917. ; 18:4, s. 895-907
-
Tidskriftsartikel (refereegranskat)abstract
- Peak-time traffic woes create considerable amount of stress and environmental pollution resulting in an economic loss. Research innovations in areas such as the Web of Things are able to curtail some of these issues by creating scalable and sustainable environments like parking lots, which provide motorists with access to convenient parking spots. We present a scalable parking lot network infrastructure that exposes parking management operations through a judicious mashup of physical things’ services within a parking lot. Our system uses service-oriented architecture, allowing motorists to reserve parking spots in advance. In doing so, our proposed system leverages the use of HTTP and Wi-Fi for the Web enablement and interoperability of things within a parking spot and elevates it as a Smart Parking Spot on the Web. Our suggested semantic Web-based structure for representing things makes it possible to query physical things’ states and services depending on their capabilities and other relevant parking-related parameters. Our performance evaluation reveals that a maximum of 40 % time is saved to find parking spots and also 40 % reduction in air pollution is observed.
|
|
| 20. |
- Mathew, Sujith Samuel, et al.
(författare)
-
The Web of Things : Challenges and Enabling Technologies
- 2013
-
Ingår i: Internet of Things and Inter-cooperative Computational Technologies for Collective Intelligence. - Berlin, Heidelberg : Springer Berlin/Heidelberg. - 9783642349522 - 9783642349515 ; , s. 1-23
-
Bokkapitel (refereegranskat)abstract
- The Internet of Things (IoT) is an active research area, focusing on connecting real-world things over TCP/IP. This trend has recently triggered the research community to adopt the interoperability of the Web (HTTP) as an application platform for integrating ‘things’ on the Internet. Harnessing physical things into the virtual world using Web standards is also enriching the arena of conventional Web services to unleash data and functions of real-world things as service providers and consumers on the Internet. This evolution of the Web as a highly interoperable application platform for connecting real-world things has raised many research challenges and problems, leading to the fast growing research area called the Web of Things (WoT). Current research on WoT is a catalyst for the realization of IoT, opening up the possibilities of creating ambient spaces (AS), where people and things seamlessly communicate over the Web. In this chapter we discuss the state of the art in WoT research, focusing on the various challenges, and enabling technologies that are driving this research. We discuss architectural frameworks, models and technologies to build applications for future ambient spaces with the WoT. We present case studies that reflect the feasibility and applicability of the WoT technology. We also discuss future trends and research directions within this domain to throw light on existing problems and challenges.
|
|
| 21. |
|
|
| 22. |
- Nemes, Szilard, 1977, et al.
(författare)
-
Integrative genomics with mediation analysis in a survival context
- 2013
-
Ingår i: Computational and mathematical methods in medicine. - : Hindawi Limited. - 1748-6718 .- 1748-670X. ; 2013, s. 413783-
-
Tidskriftsartikel (refereegranskat)abstract
- DNA copy number aberrations (DCNA) and subsequent altered gene expression profiles may have a major impact on tumor initiation, on development, and eventually on recurrence and cancer-specific mortality. However, most methods employed in integrative genomic analysis of the two biological levels, DNA and RNA, do not consider survival time. In the present note, we propose the adoption of a survival analysis-based framework for the integrative analysis of DCNA and mRNA levels to reveal their implication on patient clinical outcome with the prerequisite that the effect of DCNA on survival is mediated by mRNA levels. The specific aim of the paper is to offer a feasible framework to test the DCNA-mRNA-survival pathway. We provide statistical inference algorithms for mediation based on asymptotic results. Furthermore, we illustrate the applicability of the method in an integrative genomic analysis setting by using a breast cancer data set consisting of 141 invasive breast tumors. In addition, we provide implementation in R.
|
|
| 23. |
- Nyqvist, Jenny, et al.
(författare)
-
Genetic alterations associated with multiple primary malignancies.
- 2021
-
Ingår i: Cancer medicine. - : Wiley. - 2045-7634. ; 10:13, s. 4465-4477
-
Tidskriftsartikel (refereegranskat)abstract
- Breast cancer (BC) patients are frequently at risk of developing other malignancies following treatment. Although studies have been conducted to elucidate the etiology of multiple primary malignancies (MPM) after a BC diagnosis, few studies have investigated other previously diagnosed primary malignancies (OPPM) before BC. Here, genome-wide profiling was used to identify potential driver DNA copy number alterations and somatic mutations that promote the development of MPMs. To compare the genomic profiles for two primary tumors (BC and OPPM) from the same patient, tumor pairs from 26 young women (≤50years) diagnosed with one or more primary malignancies before breast cancer were analyzed. Malignant melanoma was the most frequent OPPM, followed by gynecologic- and hematologic malignancies. However, significantly more genetic alterations were detected in BC compared to the OPPM. BC also showed more genetic similarity as a group than the tumor pairs. Clonality testing showed that genetic alterations on chromosomes 1, 3, 16, and 19 were concordant in both tumors in 13 patients. TP53 mutations were also found to be prevalent in BC, MM, and HM. Although all samples were classified as genetically unstable, chromothripsis-like patterns were primarily observed in BC. Taken together, few recurrent genetic alterations were identified in both tumor pairs that can explain the development of MPMs in the same patient. However, larger studies are warranted to further investigate key driver mutations associated with MPMs.
|
|
| 24. |
- Nyqvist, Jenny, et al.
(författare)
-
Metachronous and synchronous occurrence of 5 primary malignancies in a female patient between 1997 and 2013 : A case report with germline and somatic genetic analysis
- 2017
-
Ingår i: Case Reports in Oncology. - : S. Karger AG. - 1662-6575. ; 10:3, s. 1006-1012
-
Tidskriftsartikel (refereegranskat)abstract
- The number of patients with multiple primary malignancies has been increasing steadily in recent years. In the present study, we describe a unique case of an 81-year-old woman with 5 metachronous and synchronous primary malignant neoplasms. The patient was first diagnosed with an endometrium adenocarcinoma in 1997 and a colon adenocarcinoma in 2002. Eleven years after her colon surgery, in 2013, the patient presented with 3 other primary malignancies within a 4-month time span: An invasive malignant melanoma on the lower leg, an invasive mucinous breast carcinoma in the right breast, and a pleomorphic spindle cell sarcoma on the left upper arm. Subsequent routine medical checkups in 2013-2017 revealed no metastases of the primary malignancies. The patient mentioned a familial aggregation of malignant tumors, including 2 sisters with breast cancer and a brother with lung cancer. Interestingly, next-generation sequencing analysis of the patient's blood sample detected no mutations in the BRCA1, BRCA2, TP53, PTEN, CDH1, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11, BMPR1A, SMAD4, PTEN, POLE, POLD1, GREM1, and GALNT12 genes. Therefore, whole genome sequencing is warranted to identify cancer-related genetic alterations in this patient with quintuple primary malignancies.
|
|
| 25. |
- Nyqvist, Jenny, et al.
(författare)
-
Previously diagnosed multiple primary malignancies in patients with breast carcinoma in Western Sweden between 2007 and 2018.
- 2020
-
Ingår i: Breast cancer research and treatment. - : Springer Science and Business Media LLC. - 1573-7217 .- 0167-6806. ; 184, s. 221-228
-
Tidskriftsartikel (refereegranskat)abstract
- Multiple primary malignancies (MPMs) caused by breast cancer treatment are well described, but only few studies to date describe which other previous primary malignancies (OPPMs) occur before breast cancer. The purpose of the present study was to evaluate the prevalence of OPPMs in patients with breast cancer between 2007 and 2018 in Western Sweden.Patient selection was performed using both pathology reports at Sahlgrenska University Hospital (Sweden) and the Swedish Cancer Registry. All newly diagnosed breast cancer patients were screened for presence of OPPM.In total, 8031 breast cancer patients were diagnosed at Sahlgrenska University Hospital between 2007 and 2018. The prevalence of breast cancer patients with OPPMs (n=414) increased from on average 2.6% to 8.2% during this 12-year period and ranged from 17 to 59 patients annually.The most striking increase in prevalence was found among the gynecological tumors (endometrium and ovarian adenocarcinomas), malignant melanomas and gastrointestinal malignancies.These findings were validated using data of the Swedish Cancer Registry.The overall survival rates for cancer patients have improved tremendously during the past 40years, in part due to individually tailored therapies and screening programs. Our study revealed an increasing trend of OPPMs in breast cancer patients.
|
|
| 26. |
- Oparina, Nina, et al.
(författare)
-
Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.
- 2021
-
Ingår i: Cancers. - : MDPI AG. - 2072-6694. ; 13:9
-
Tidskriftsartikel (refereegranskat)abstract
- Breast cancer (BC) histological and molecular classifications significantly improved the treatment strategy and prognosis. Inhibitor of apoptosis BIRC5/survivin is often overexpressed in cancers, however, indications of its importance in BC are inconsistent. We integrate BIRC5 protein and mRNA measures with clinical associates and long-term outcome in three independent cohorts Protein levels of BIRC5 were measured in primary lysates of 845 patients of the West Swedish BC cohort (VGR-BC) and linked to 5- and 27-years survival. The results were externally validated in transcriptomic data from METABRIC and SCAN-B cohorts. Survival analysis showed that high levels of BIRC5 were consistently associated with a poor probability of 5-year overall survival. High BIRC5 in VGR-BC contributed negatively to the disease-specific survival at 5 and 27 years. Subsets with different status by ER (estrogen receptor) expression and presence of nodal metastasis supported independent association of high BIRC5 with poor prognosis in all cohorts. In METABRIC and SCAN-B cohorts, high levels of BIRC5 mRNA were associated with the basal-like and luminal B molecular BC subtypes and with increasing histologic grade. BIRC5 is a sensitive survival marker that acts independent of ER and nodal status, and its levels need to be considered when making treatment decisions.
|
|
| 27. |
|
|
| 28. |
|
|
| 29. |
- Shubbar, Emman, 1974, et al.
(författare)
-
Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.
- 2013
-
Ingår i: BMC cancer. - : Springer Science and Business Media LLC. - 1471-2407. ; 13:1
-
Tidskriftsartikel (refereegranskat)abstract
- ABSTRACT: BACKGROUND: Breast cancer is a potentially fatal malignancy in females despite the improvement in therapeutic techniques. The identification of novel molecular signatures is needed for earlier detection, monitoring effects of treatment, and predicting prognosis. We have previously used microarray analysis to identify differentially expressed genes in aggressive breast tumors. The purpose of the present study was to investigate the prognostic value of the candidate biomarkers CCNB2, ASPM, CDCA7, KIAA0101, and SLC27A2 in breast cancer. METHODS: The expression levels and subcellular localization of the CCNB2, ASPM, CDCA7, KIAA0101, and SLC27A2 proteins were measured using immunohistochemistry (IHC) on a panel of 80 primary invasive breast tumors. Furthermore, the mRNA levels of CCNB2, KIAA0101, and SLC27A2 were subsequently examined by qRT-PCR to validate IHC results. Patient disease-specific survival (DSS) was evaluated in correlation to protein levels using the Kaplan-Meier method. Multivariate Cox regression analysis was used to determine the impact of aberrant protein expression of the candidate biomarkers on patient DSS and to estimate the hazard ratio at 8-year follow-up. RESULTS: Elevated cytoplasmic CCNB2 protein levels were strongly associated with short-term disease-specific survival of breast cancer patients (<= 8 years; P<0.001) and with histological tumor type (P= 0.04). However, no association with other clinicopathological parameters was observed. Multivariate Cox regression analysis specified that CCNB2 protein expression is an independent prognostic marker of DSS in breast cancer. The predictive ability of several classical clinicopathological parameters was improved when used in conjunction with CCNB2 protein expression (C-index = 0.795) in comparison with a model without CCNB2 expression (C-index = 0.698). The protein levels of ASPM, CDCA7, KIAA0101, and SLC27A2 did not correlate with any clinicopathological parameter and had no influence on DSS. However, a significant correlation between the expression of the CCNB2 and ASPM proteins was detected (P = 0.03). CONCLUSION: These findings suggest that cytoplasmic CCNB2 may function as an oncogene and could serve as a potential biomarker of unfavorable prognosis over short-term follow-up in breast cancer.
|
|
